| For Practicing Rheumatologists |
  See all
|
Article Summary
|
|
|
He J et al. - Mucosal administration of alpha-fodrin effectively inhibited the progression of experimental Sjogren's syndrome autoimmunity. Methods- 4-wk-old NOD mice were immunized with a 1 µg or 10 µg dose of alpha-fodrin every other day; GST and PBS served as controls
- In immunized animals, the salivary flow was maintained
- The animals were analyzed for the presence of anti-SSA, anti-SSB, RF, ANA, anti-alpha-fodrin, and anti-type 3 muscarinic acetylcholine receptor polypeptide (M3RP) by IFC or ELISA
- The cytokines IFN-gamma and IL-10 were measured by ELISA
- Salivary glands were examined by H&E staining and IHC analysis
- Water volume intake was calculated for each group
- The induction of regulatory T cells was assessed by FACS analysis for the frequency of Foxp3+ cells among peripheral CD4+CD25+ T cells
Results- The appearance of anti-alpha-fodrin and -M3RP antibodies was delayed in mice immunized with alpha-fodrin
- The titers of anti-alpha-fodrin and M3RP antibodies were lower in immunized mice
- 5/8 mice in the GST group, 5/8 mice in the PBS group, 2/8 mice in the alpha-fodrin 1 µg/dose group, and 3/8 mice in the alpha-fodrin 10 µg/dose were positive for ANA
- The number of Foxp3+ CD4+CD25+ regulatory T cells was higher in the alpha-fodrin groups vs controls
- Lymphocytic infiltration and expression of alpha-fodrin in the salivary glands was decreased in alpha-fodrin-treated groups
|
 |
|
| Read a Different Specialty |
 |
|
|
|
|
| Profession Index |
|
|
|
|
|
|
|
